ZA964759B - Antithrombotic petidoyl heterocycles. - Google Patents

Antithrombotic petidoyl heterocycles.

Info

Publication number
ZA964759B
ZA964759B ZA9604759A ZA964759A ZA964759B ZA 964759 B ZA964759 B ZA 964759B ZA 9604759 A ZA9604759 A ZA 9604759A ZA 964759 A ZA964759 A ZA 964759A ZA 964759 B ZA964759 B ZA 964759B
Authority
ZA
South Africa
Prior art keywords
petidoyl
antithrombotic
heterocycles
thrombin
compounds
Prior art date
Application number
ZA9604759A
Other languages
English (en)
Inventor
Michael J Costanzo
Bruce E Maryanoff
Original Assignee
Ortho Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Pharma Corp filed Critical Ortho Pharma Corp
Publication of ZA964759B publication Critical patent/ZA964759B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/022—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
    • C07K5/0222—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2 with the first amino acid being heterocyclic, e.g. Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C07K5/06095—Arg-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA9604759A 1995-06-07 1996-06-06 Antithrombotic petidoyl heterocycles. ZA964759B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/486,473 US5523308A (en) 1995-06-07 1995-06-07 Peptidyl heterocycles useful in the treatment of thrombin related disorders

Publications (1)

Publication Number Publication Date
ZA964759B true ZA964759B (en) 1997-12-08

Family

ID=23932026

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9604759A ZA964759B (en) 1995-06-07 1996-06-06 Antithrombotic petidoyl heterocycles.

Country Status (21)

Country Link
US (1) US5523308A (pl)
EP (1) EP0833839B1 (pl)
JP (1) JPH11506762A (pl)
KR (1) KR100434667B1 (pl)
CN (1) CN1146575C (pl)
AT (1) ATE230757T1 (pl)
AU (1) AU721079B2 (pl)
CA (1) CA2224110A1 (pl)
CZ (1) CZ386997A3 (pl)
DE (1) DE69625691T2 (pl)
DK (1) DK0833839T3 (pl)
ES (1) ES2191102T3 (pl)
IL (1) IL122436A (pl)
MX (1) MX9709915A (pl)
NO (1) NO975747L (pl)
NZ (1) NZ309523A (pl)
PL (1) PL184986B1 (pl)
RU (1) RU2181125C2 (pl)
TW (1) TW470751B (pl)
WO (1) WO1996040748A1 (pl)
ZA (1) ZA964759B (pl)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4857633A (en) * 1984-06-25 1989-08-15 Exxon Research & Engineering Company Method for high temperature phase separation of solutions containing polymers
US5721214A (en) * 1995-06-07 1998-02-24 Cor Therapeutics, Inc. Inhibitors of factor Xa
US5827860A (en) * 1995-06-07 1998-10-27 Ortho Pharmaceutical Corporation Peptidyl heterocycles useful in the treatment of thrombin related disorders
US6022861A (en) * 1995-06-07 2000-02-08 Cor Therapeutics, Inc. Ketoheterocyclic inhibitors of factor Xa
US6069130A (en) * 1995-06-07 2000-05-30 Cor Therapeutics, Inc. Ketoheterocyclic inhibitors of factor Xa
US5919765A (en) * 1995-06-07 1999-07-06 Cor Therapeutics, Inc. Inhibitors of factor XA
US6211154B1 (en) 1995-06-07 2001-04-03 Cor Therapeutics, Inc. Ketoheterocyclic inhibitors of factor Xa
US5827866A (en) * 1995-06-07 1998-10-27 Ortho Pharmaceutical Corporation Peptidyl heterocycles useful in the treatment of thrombin related disorders
US6046169A (en) * 1995-06-07 2000-04-04 Cor Therapeutics, Inc. Inhibitors of factor XA
IL119466A (en) 1995-11-03 2001-08-26 Akzo Nobel Nv Thrombin inhibitors, their preparation and pharmaceutical compositions containing them
US5811402A (en) * 1996-03-22 1998-09-22 Eli Lilly And Company Antithrombotic diamides
US6245743B1 (en) 1996-06-05 2001-06-12 Cor Therapeutics, Inc. Inhibitors of factor Xa
WO1998016524A1 (en) * 1996-10-11 1998-04-23 Cor Therapeutics, Inc. HETEROCYCLIC DERIVATIVES AS FACTOR Xa INHIBITORS
US6063794A (en) 1996-10-11 2000-05-16 Cor Therapeutics Inc. Selective factor Xa inhibitors
US6369080B2 (en) 1996-10-11 2002-04-09 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6262047B1 (en) 1996-10-11 2001-07-17 Cor Therapeutics, Inc. Selective factor Xa inhibitors
AU743544B2 (en) * 1996-10-11 2002-01-31 Millennium Pharmaceuticals, Inc. Selective factor Xa inhibitors
EP0932615A1 (en) * 1996-10-11 1999-08-04 Cor Therapeutics, Inc. SELECTIVE FACTOR Xa INHIBITORS
US6194435B1 (en) * 1996-10-11 2001-02-27 Cor Therapeutics, Inc. Lactams as selective factor Xa inhibitors
NZ500352A (en) 1997-04-14 2001-10-26 Cor Therapeutics Inc Cyclic diaza selective factor Xa inhibitors
US6133256A (en) * 1997-04-14 2000-10-17 Cor Therapeutics Inc Selective factor Xa inhibitors
US6204268B1 (en) 1997-04-14 2001-03-20 Cor Therapeutics, Inc Selective factor Xa inhibitors
US5877156A (en) * 1997-04-24 1999-03-02 Akzo Nobel, N.V. Thrombin inhibitors
EP0884325A1 (en) * 1997-04-24 1998-12-16 Akzo Nobel N.V. Thrombin inhibitors containing a peptidyl heterocycle
US6214841B1 (en) 1997-05-15 2001-04-10 Eli Lilly And Company Antithrombotic compound
AU2006252275A1 (en) * 1997-07-28 2007-01-25 Johnson & Johnson Consumer Companies, Inc. Methods for treating skin pigmentation
US8039026B1 (en) * 1997-07-28 2011-10-18 Johnson & Johnson Consumer Companies, Inc Methods for treating skin pigmentation
US6218382B1 (en) 1997-08-11 2001-04-17 Cor Therapeutics, Inc Selective factor Xa inhibitors
US6333321B1 (en) 1997-08-11 2001-12-25 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6228854B1 (en) 1997-08-11 2001-05-08 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6323219B1 (en) 1998-04-02 2001-11-27 Ortho-Mcneil Pharmaceutical, Inc. Methods for treating immunomediated inflammatory disorders
US6750229B2 (en) 1998-07-06 2004-06-15 Johnson & Johnson Consumer Companies, Inc. Methods for treating skin pigmentation
US8093293B2 (en) * 1998-07-06 2012-01-10 Johnson & Johnson Consumer Companies, Inc. Methods for treating skin conditions
US8106094B2 (en) 1998-07-06 2012-01-31 Johnson & Johnson Consumer Companies, Inc. Compositions and methods for treating skin conditions
CZ20012722A3 (cs) * 1999-01-27 2002-08-14 Ortho-Mcneil Pharmaceutical, Inc. Peptidylové heterocyklické ketony pouľitelné jako inhibitory typtasy
US7985404B1 (en) 1999-07-27 2011-07-26 Johnson & Johnson Consumer Companies, Inc. Reducing hair growth, hair follicle and hair shaft size and hair pigmentation
US7309688B2 (en) 2000-10-27 2007-12-18 Johnson & Johnson Consumer Companies Topical anti-cancer compositions and methods of use thereof
GB0004686D0 (en) * 2000-02-28 2000-04-19 Aventis Pharma Ltd Chemical compounds
SI20582A (sl) * 2000-05-05 2001-12-31 Univerza V Ljubljani Novi inhibitorji trombina, njihova priprava in uporaba
US6960597B2 (en) * 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
DE10046934A1 (de) * 2000-09-21 2002-04-18 Consortium Elektrochem Ind Verfahren zur fermentativen Herstellung von nicht-proteinogenen L-Aminosäuren
US8431550B2 (en) 2000-10-27 2013-04-30 Johnson & Johnson Consumer Companies, Inc. Topical anti-cancer compositions and methods of use thereof
US7192615B2 (en) 2001-02-28 2007-03-20 J&J Consumer Companies, Inc. Compositions containing legume products
US6555143B2 (en) 2001-02-28 2003-04-29 Johnson & Johnson Consumer Products, Inc. Legume products
KR20030080810A (ko) * 2002-04-11 2003-10-17 주식회사 엘지생명과학 아미노피리도아릴 그룹을 가진 선택적 트롬빈 억제제
AU2003231016A1 (en) * 2002-04-16 2003-10-27 Aventis Pharmaceuticals, Inc., Process for preparing heteroaryl and unsaturated heterocycloalkylmagnesium reagents and uses
US7375093B2 (en) * 2002-07-05 2008-05-20 Intrexon Corporation Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
US20040063593A1 (en) * 2002-09-30 2004-04-01 Wu Jeffrey M. Compositions containing a cosmetically active organic acid and a legume product
US7393920B2 (en) 2003-06-23 2008-07-01 Cem Corporation Microwave-assisted peptide synthesis
US20050176755A1 (en) * 2003-10-31 2005-08-11 Dyatkin Alexey B. Aza-bridged-bicyclic amino acid derivatives as alpha4 integrin antagonists
KR20070001976A (ko) * 2004-02-10 2007-01-04 얀센 파마슈티카 엔.브이. 알파４ 인테그린의 길항제로서의 피리다지논 우레아
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
US7951823B2 (en) * 2006-05-23 2011-05-31 Irm Llc Compounds and compositions as channel activating protease inhibitors
CN101443348A (zh) * 2006-05-23 2009-05-27 Irm责任有限公司 作为通道活化蛋白酶抑制剂的化合物和组合物
TWI389899B (zh) * 2006-08-08 2013-03-21 Msd Oss Bv 具口服活性之凝血酶抑制劑
EA016327B1 (ru) * 2007-02-09 2012-04-30 Айрм Ллк Соединения и композиции в качестве ингибиторов протеазы, активирующей каналы
CN101646437A (zh) * 2007-02-09 2010-02-10 Irm责任有限公司 作为通道活化蛋白酶抑制剂的化合物和组合物
EP2714716B1 (en) 2011-06-02 2018-04-11 Socpra Sciences Santé Et Humaines S.E.C. Matriptase inhibitors and uses thereof against orthomyxoviridae infections
CN104003984B (zh) * 2014-06-16 2016-03-02 山东大学 噻唑-4-甲酰基哌嗪衍生物及其制备方法与应用
MX378266B (es) 2014-10-06 2025-03-10 Lighthouse Pharmaceuticals Inc Inhibidores de gingipaina de lisina.
CN108602787A (zh) * 2015-11-09 2018-09-28 库特克希米公司 精氨酸牙龈卟啉菌蛋白酶的抑制剂
CN109983012B (zh) 2016-09-16 2023-12-01 莱特豪斯制药公司 赖氨酸牙龈蛋白酶的酮抑制剂
US20190309020A1 (en) * 2016-11-22 2019-10-10 Ohio State Innovation Foundation Cell-penetrating peptide sequences
US11352394B2 (en) 2016-11-22 2022-06-07 Ohio State Innovation Foundation Cyclic cell penetrating peptides comprising beta-hairpin motifs and methods of making and using thereof
WO2019070962A1 (en) 2017-10-04 2019-04-11 Ohio State Innovation Foundation BICYCLIC PEPTIDE INHIBITORS
EP3746105A4 (en) 2018-01-29 2022-05-18 Ohio State Innovation Foundation CYCLIC PEPTIDYLIN HIBITORS OF THE CAL-PDZ-BINDING DOMAIN
EP3790890A4 (en) 2018-05-09 2022-03-02 Ohio State Innovation Foundation CYCLIC, CELL-PENETRATING PEPTIDES WITH ONE OR MORE HYDROPHOBIC RAILS
WO2020010103A1 (en) 2018-07-02 2020-01-09 Ohio State Innovation Foundation Polypeptide conjugates for intracellular delivery of nucleic acids
CN117143179B (zh) * 2023-09-18 2024-07-12 安徽峆一药业股份有限公司 一种凝血酶发色底物s-2238的合成方法
CN118754827B (zh) * 2024-06-27 2025-03-25 成都普康唯新生物科技有限公司 含保护基的α-甲基鸟氨酸的合成方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5332726A (en) * 1989-09-29 1994-07-26 Rhone-Poulenc Rorer Pharmaceuticals Inc. Antithrombotic peptides and pseudopeptides
EP0503203A1 (en) * 1991-03-15 1992-09-16 Merrell Dow Pharmaceuticals Inc. Novel thrombin inhibitors
WO1993016081A1 (en) * 1992-02-13 1993-08-19 Merrell Dow Pharmaceuticals Inc. Piperidinyl thiacyclic derivatives
SE9301916D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
EP0648780A1 (en) * 1993-08-26 1995-04-19 Bristol-Myers Squibb Company Heterocyclic thrombin inhibitors
JPH0820597A (ja) * 1994-07-07 1996-01-23 Meiji Seika Kaisha Ltd トロンビン阻害作用を有する複素環カルボニル化合物

Also Published As

Publication number Publication date
PL323825A1 (en) 1998-04-27
NO975747D0 (no) 1997-12-05
KR19990022568A (ko) 1999-03-25
CN1146575C (zh) 2004-04-21
IL122436A (en) 2004-06-20
JPH11506762A (ja) 1999-06-15
EP0833839A1 (en) 1998-04-08
AU721079B2 (en) 2000-06-22
KR100434667B1 (ko) 2004-09-24
RU2181125C2 (ru) 2002-04-10
MX9709915A (es) 1998-08-30
ES2191102T3 (es) 2003-09-01
DK0833839T3 (da) 2003-04-14
ATE230757T1 (de) 2003-01-15
NZ309523A (en) 1999-11-29
WO1996040748A1 (en) 1996-12-19
EP0833839B1 (en) 2003-01-08
TW470751B (en) 2002-01-01
US5523308A (en) 1996-06-04
DE69625691T2 (de) 2003-10-23
PL184986B1 (pl) 2003-01-31
CN1192747A (zh) 1998-09-09
AU5971396A (en) 1996-12-30
CA2224110A1 (en) 1996-12-19
NO975747L (no) 1998-02-03
CZ386997A3 (cs) 1998-07-15
DE69625691D1 (de) 2003-02-13

Similar Documents

Publication Publication Date Title
ZA964759B (en) Antithrombotic petidoyl heterocycles.
MX9707570A (es) Utilizacion de agonistas de alta1l para el tratamiento de la incontinencia urinaria.
AU2490297A (en) Use of strontium salts for the production of pharmaceutical compositions intended for the treatment of arthrosis
AP9600804A0 (en) Therapeutic amides.
BG102425A (en) (methylsulphonyl)phenyl-2-(5h)-furanons as cyclooxygenase-2-inhibitors
MX9704030A (es) 1,1-dioxidos de 2-heterocicliloxi y tiometil-1,2,5-tiadiazolidin-3-ona y composiciones y metodo de uso de los mismos.
AU5648496A (en) Pyrazolo-(1,5a)pyrimidines, their preparation and their use
AU5967896A (en) Peptidyl heterocycles useful in the treatment of thrombin re lated disorders
IL115589A0 (en) Use of cck-b antagonists in pharmaceutical compositions
ZA964761B (en) Peptidyl heterocycles useful in the treatment of thrombin related disorders.
AU7310896A (en) Use of nitroflavonoids for the treatment of anxiety
AU3745895A (en) Use of gaba antagonists in the treatment of emesis
TW330933B (en) Furanoeremophilane and eremophilanolide sesquiterpenes for treatment of diabetes
GB9526691D0 (en) Medical use of proteases
AU4546096A (en) Treatment of waste
MX9603087A (es) Procedimiento para la obtencion de aminocarboniltriazolinonas substituidas.
AU4319393A (en) Use of indolocarbazols in aids treatment
DE69526731D1 (en) Hypocholesterolämische,antiatherosklerotische und hypotriglyceridämische mercaptoacetylamid-derivate
WO1996026728A3 (en) Use of moxonidine for the treatment of atherosclerosis
AP2000001963A0 (en) Paroxetine ascorbate.
GR3034688T3 (en) Use of 6,7-substituted-2-aminotetralines for preparing pharmaceutical compositions useful for the treatment of septic shock, and antipyretic and antiinflammatory pharmaceutical compositions
FR2759290B1 (fr) Minalcipran pour le traitement de l'incontinence urinaire
CA2248753A1 (en) Use of olanzapine for treating excessive aggression
NZ282565A (en) Condensed mercaptoacetylamidedisulphidebenzazepines used in treating elevated cholesterol levels, atherosclerosis, and hypotriglyceridemia
GB9408916D0 (en) Treatment of sewage